Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLOXACILLIN

Form:

8 of 8 products shown

5 general benefit · 3 not a benefit

Other products in the same Health Canada class (J01C) — coverage varies; not interchangeable

  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit

Teva-Cloxacillin · DIN 00337757 · 25mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cloxacillin · DIN 00337757 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $2.4240 Health Canada: Marketed since 2016-09-29 · brand TEVA-CLOXACILLIN · ATC J01CF02 CLOXACILLIN · form Granules for solution · route Oral · ingredients CLOXACILLIN (CLOXACILLIN SODIUM) 125 MG/5ML · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Cloxacillin: Formulary list price $0.0606/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0606 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3794 · Verify on the e-Formulary ↗ (DIN 00337757)

Source record
DIN 00337757: Teva-Cloxacillin Raw flags: sec3=Y Item: 081216009; group id 28; item number 0059; lccId None; manufacturer id TEV Source form: O/L; strength: 25mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0606; ministry $0.0606 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00337757 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3794
Interchangeable products
Orbenin · DIN 02042975 · not recorded
Shortage status: resolved shortage (ended 2025-10-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00337757
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Cloxacillin · DIN 02510731 · 250mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Cloxacillin · DIN 02510731 Manufacturer: Jamp Pharma Corporation; listing date 2022-12-21 Daily cost (source): $0.8564 Health Canada: Marketed since 2022-02-17 · brand JAMP CLOXACILLIN · ATC J01CF02 CLOXACILLIN · form Capsule · route Oral · ingredients CLOXACILLIN (CLOXACILLIN SODIUM) 250 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Cloxacillin: Formulary list price $0.2141/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2141 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99993 · Verify on the e-Formulary ↗ (DIN 02510731)

Source record
DIN 02510731: Jamp Cloxacillin Raw flags: sec3=Y Item: 081216008; group id 28; item number 0057; lccId None; manufacturer id JPC Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.2141; ministry $0.2141 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510731 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99993
Interchangeable products
Orbenin · DIN 00002046 · not recorded Teva-Cloxacillin · DIN 00337765 · $0.2141
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510731
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Cloxacillin · DIN 00337765 · 250mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cloxacillin · DIN 00337765 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $0.8564 Health Canada: Marketed since 2016-09-29 · brand TEVA-CLOXACILLIN · ATC J01CF02 CLOXACILLIN · form Capsule · route Oral · ingredients CLOXACILLIN (CLOXACILLIN SODIUM) 250 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Cloxacillin: Formulary list price $0.2141/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2141 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2233 · Verify on the e-Formulary ↗ (DIN 00337765)

Source record
DIN 00337765: Teva-Cloxacillin Raw flags: sec3=Y Item: 081216008; group id 28; item number 0057; lccId None; manufacturer id TEV Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.2141; ministry $0.2141 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00337765 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2233
Interchangeable products
Jamp Cloxacillin · DIN 02510731 · $0.2141 Orbenin · DIN 00002046 · not recorded
Shortage status: resolved shortage (ended 2022-09-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00337765
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Cloxacillin · DIN 02510758 · 500mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Cloxacillin · DIN 02510758 Manufacturer: Jamp Pharma Corporation; listing date 2022-12-21 Daily cost (source): $1.6180 Health Canada: Marketed since 2022-02-17 · brand JAMP CLOXACILLIN · ATC J01CF02 CLOXACILLIN · form Capsule · route Oral · ingredients CLOXACILLIN (CLOXACILLIN SODIUM) 500 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Cloxacillin: Formulary list price $0.4045/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4045 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99994 · Verify on the e-Formulary ↗ (DIN 02510758)

Source record
DIN 02510758: Jamp Cloxacillin Raw flags: sec3=Y Item: 081216007; group id 28; item number 0058; lccId None; manufacturer id JPC Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.4045; ministry $0.4045 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510758 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99994
Interchangeable products
Orbenin · DIN 00002054 · not recorded Teva-Cloxacillin · DIN 00337773 · $0.4045
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510758
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Cloxacillin · DIN 00337773 · 500mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cloxacillin · DIN 00337773 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $1.6180 Health Canada: Marketed since 2016-09-29 · brand TEVA-CLOXACILLIN · ATC J01CF02 CLOXACILLIN · form Capsule · route Oral · ingredients CLOXACILLIN (CLOXACILLIN SODIUM) 500 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Cloxacillin: Formulary list price $0.4045/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4045 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2234 · Verify on the e-Formulary ↗ (DIN 00337773)

Source record
DIN 00337773: Teva-Cloxacillin Raw flags: sec3=Y Item: 081216007; group id 28; item number 0058; lccId None; manufacturer id TEV Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.4045; ministry $0.4045 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00337773 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2234
Interchangeable products
Jamp Cloxacillin · DIN 02510758 · $0.4045 Orbenin · DIN 00002054 · not recorded
Shortage status: resolved shortage (ended 2023-08-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00337773
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Orbenin · DIN 02042975 · 25mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-01-28 — choose a marketed DIN from the same-category list.Discontinued 1998-01-28 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-01-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-01-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Orbenin · DIN 02042975 Manufacturer: Wyeth Pharmaceuticals; listing date 1996-10-01 Daily cost (source): $2.4240 Health Canada: Cancelled post market since 1998-01-28 · brand ORBENIN PWS 125MG/5ML · ATC J01CF02 CLOXACILLIN · form Powder for solution · route Oral · ingredients CLOXACILLIN (CLOXACILLIN SODIUM) 125 MG/5ML · company Wyeth-ayerst canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Orbenin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19122 · Verify on the e-Formulary ↗ (DIN 02042975)

Source record
DIN 02042975: Orbenin Raw flags: notABenefit=Y, sec3=Y Item: 081216009; group id 28; item number 0059; lccId None; manufacturer id WAY Source form: O/L; strength: 25mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042975 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19122
Interchangeable products
Teva-Cloxacillin · DIN 00337757 · $0.0606
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02042975
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1998-01-28 — choose a marketed DIN from the same-category list.

Orbenin · DIN 00002046 · 250mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-12-15 — choose a marketed DIN from the same-category list.Discontinued 1998-12-15 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-12-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-12-15 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Orbenin · DIN 00002046 Manufacturer: Ayerst Laboratories, Division of Ayerst, McKenna & Harrison; listing date 1996-10-01 Daily cost (source): $0.8564 Health Canada: Cancelled post market since 1998-12-15 · brand ORBENIN CAP 250MG · ATC J01CF02 CLOXACILLIN · form Capsule · route Oral · ingredients CLOXACILLIN SODIUM 250 MG/CAP · company Ayerst laboratories · schedule Prescription
Check this DIN again · Health Canada product record

Orbenin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=536 · Verify on the e-Formulary ↗ (DIN 00002046)

Source record
DIN 00002046: Orbenin Raw flags: notABenefit=Y, sec3=Y Item: 081216008; group id 28; item number 0057; lccId None; manufacturer id AYE Source form: Cap; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00002046 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=536
Interchangeable products
Jamp Cloxacillin · DIN 02510731 · $0.2141 Teva-Cloxacillin · DIN 00337765 · $0.2141
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00002046
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1998-12-15 — choose a marketed DIN from the same-category list.

Orbenin · DIN 00002054 · 500mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-11-24 — choose a marketed DIN from the same-category list.Discontinued 1997-11-24 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-11-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1997-11-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Orbenin · DIN 00002054 Manufacturer: Ayerst Laboratories, Division of Ayerst, McKenna & Harrison; listing date 1996-10-01 Daily cost (source): $1.6180 Health Canada: Cancelled post market since 1997-11-24 · brand ORBENIN CAP 500MG · ATC J01CF02 CLOXACILLIN · form Capsule · route Oral · ingredients CLOXACILLIN SODIUM 500 MG/CAP · company Ayerst laboratories · schedule Prescription
Check this DIN again · Health Canada product record

Orbenin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93 · Verify on the e-Formulary ↗ (DIN 00002054)

Source record
DIN 00002054: Orbenin Raw flags: notABenefit=Y, sec3=Y Item: 081216007; group id 28; item number 0058; lccId None; manufacturer id AYE Source form: Cap; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00002054 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93
Interchangeable products
Jamp Cloxacillin · DIN 02510758 · $0.4045 Teva-Cloxacillin · DIN 00337773 · $0.4045
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00002054
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1997-11-24 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-CLOXACILLIN (cloxacillin sodium) finds use in the treatment of infections caused by streptococci when associated with sensitive penicillinase-producing staphylococci; also in the treatment of all staphylococcal infections, whether penicillin G-sensitive or resistant. In infections suspected of being caused by penicillinase-producing staphylococci, cloxacillin may be used for initial treatment after appropriate specimens have been taken for culture and before results of microbial susceptibility tests are known. If the results of identification and susceptibility tests indicate that the infecting organism is not a penicillinase-producing staphylococcus susceptible to cloxacillin, cloxacillin should be discontinued and treatment with an appropriate alternative agent instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEVA- CLOXACILLIN and other antibacterial drugs, TEVA-CLOXACILLIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, th… https://pdf.hres.ca/dpd_pm/00055444.PDF PM date: March 17, 2020 Source product: TEVA-CLOXACILLIN; DIN 00337757; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Orbenin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026